猎魔人

2026江苏省新消费创新创业大赛“消费+人工智能”复赛在苏州举行,2026江苏省新消费创新创业大赛“消费+人工智能”复赛在苏州举行_我的网站

一 |

Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness.
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source.
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations.
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。　　苏州8月21日电 (常慕城)2026江苏省新消费创新创业大赛“消费+人工智能”复赛，21日在苏州工业园区东沙湖基金小镇启幕，共有30个创新创业项目现场开展路演。　　本次复赛涌现一批颇具代表性的创新项目：“AI深空影像机器人”聚焦深空摄影领域，帮助零基础用户一键生成高质量深空星云影像；“灵绣智造”依托苏绣基因库、数字设计生态及绣娘工作室，以数智赋能推动传统绣艺焕发新生；“智擎·灵手”面向复杂零售场景研发自适应柔性抓取机器人，重塑工业抓取的“温柔之力”。　　创业赛道方面，迈宝智能科技(苏州)有限公司带来可穿戴运动科技产品，可以通过先进技术，精准识别人体动作、发力模式与身体反馈；苏州少昊科技有限公司推进智能音箱研发及产业化，破解传统智能音箱交互生硬、功能与外观美学相割裂的行业痛点；江苏西米科技有限公司AI眼镜集成AI助手、同声传译、会议纪要等多项功能，目前已启动政企特定场景的产品研发。　　“各行各业都在积极拥抱人工智能。